Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;39(2):94-101.

Echocardiographic Evaluation of the Effects of a Single Bolus of Erythropoietin on Reducing Ischemia-Reperfusion Injuries during Coronary Artery Bypass Graft Surgery; A Randomized, Double-Blind, Placebo-Control Study

Shervin Ziabakhsh-Tabary  1 , Rozita Jalalian  2 , Farzad Mokhtari-Esbuie  3 , Mohammad Reza Habibi  4
Affiliations

Echocardiographic Evaluation of the Effects of a Single Bolus of Erythropoietin on Reducing Ischemia-Reperfusion Injuries during Coronary Artery Bypass Graft Surgery; A Randomized, Double-Blind, Placebo-Control Study

Shervin Ziabakhsh-Tabary et al. Iran J Med Sci. 2014 Mar.

Abstract

Background: Erythropoietin (EPO) is known as a regulating hormone for the production of red blood cells, called erythropoiesis. Some studies have shown that EPO exerts some non-hematopoietic protective effects on ischemia-reperfusion injuries in myocytes. Using echocardiography, we evaluated the effect of EPO infusion on reducing ischemia-reperfusion injuries and improvement of the cardiac function shortly after coronary artery bypass graft surgery (CABG).

Methods: Forty-three patients were recruited in this study and randomly divided into two groups: the EPO group, receiving standard medication and CABG surgery plus EPO (700 IU/kg), and the control group, receiving standard medication and CABG surgery plus normal saline (10 cc) as placebo. The cardiac function was assessed through echocardiography before as well as at 4 and 30 days after CABG.

Results: Echocardiography indicated that the ejection fraction had no differences between the EPO and control groups at 4 days (47.05±6.29 vs. 45.90±4.97; P=0.334) and 30 days after surgery (47.27±28 vs. 46.62±5.7; P=0.69). There were no differences between the EPO and control groups in the wall motion score index at 4 (P=0.83) and 30 days after surgery (P=0.902). In the EPO group, there was a reduction in left ventricular end-systolic and end-diastolic diameters (LVESD and LVEDD, respectively), as compared to the control group.

Conclusion: Our results indicated that perioperative exogenous EPO infusion could not improve the ventricular function and wall motion index in the immediate post-CABG weeks. Nevertheless, a reduction in LVEDD and LVESD at 4 days and 30 days after CABG in the EPO group, by comparison with the control group, suggested that EPO correlated with a reduction in the remodeling of myocytes and reperfusion injuries early after CABG.

Trial registration number: 138809102799N1.

Keywords: Coronary artery bypass graft; Erythropoietin; Ischemia; Reperfusion injury.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The patient’s consort flow chart is illustrated above.
Figure 2
Figure 2
Wall motion score index before and after coronary artery bypass graft surgery in both groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Adamson JW, Longo DL. Anemia and polycythemia. Hematologic alterations. In: Fauci A, Braunwald E, Kasper D, editors. Harrison’s principle of internal medicine. 17th ed. Vol. 2. New York: McGraw Hill; 2008. pp. 329–37.
    1. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle, Cerami C, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A. 2000;97:10526–31. doi: 10.1073/pnas.97.19.10526. PubMed PMID: 10984541; PubMed Central PMCID: PMC27058. - PMC - PubMed
    1. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 2004;19: 348–55. doi: 10.1093/ndt/gfg547. PubMed PMID: 14736958. - PubMed
    1. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2002;99:10659–64. doi: 10.1073/pnas.152321399. PubMed PMID: 12130665; PubMed Central PMCID: PMC125005. - PMC - PubMed
    1. Ogilvie M, Yu X, Nicolas-Metral V, Pulido SM, Liu C, Ruegg UT, et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem. 2000;275:39754–61. doi: 10.1074/jbc.M004999200. PubMed PMID: 10995753. - PubMed